91224-37-2
中文名稱
(D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P
英文名稱
D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2 HYDROCHLORIDE
CAS
91224-37-2
分子式
C75H108N20O13
分子量
1497.79
MOL 文件
91224-37-2.mol
更新日期
2024/12/16 10:25:30
91224-37-2 結(jié)構(gòu)式
基本信息
中文別名
化合物 T20413D-ARG1,D-TRP7,9,LEU11]神經(jīng)肽P物質(zhì)
英文別名
SPANTIDESPANTIDE I
(D-Arg1,D-Trp7
SPANTIDE HYDROCHLORIDE
M.W. 1497.80 C75H108N20O13
1-Arg-7,9-Trp-11-Leu-substance p
(D-ARG1,D-TRP7,9,LEU11)-SUBSTANCE P
[D-Arg1,D-Trp7,9,L-Leu11]substance P
Substance p, Arg(1)-Trp(7,9)-Leu(11)-
SUBSTANCE P, [D-ARG1, D-TRP7,9, LEU11]
物理化學(xué)性質(zhì)
密度1.43±0.1 g/cm3(Predicted)
儲存條件−20°C
酸度系數(shù)(pKa)13.31±0.20(Predicted)
形態(tài)粉末
顏色White to off-white
水溶解性Soluble to 1 mg/ml in water
(D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | HY-P1194 | (D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P Spantide I | 91224-37-2 | 1 mg | 550元 |
| 2024/11/08 | HY-P1194 | (D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P Spantide I | 91224-37-2 | 5 mg | 1650元 |
| 2024/11/08 | HY-P1194 | (D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P Spantide I | 91224-37-2 | 10 mg | 2450元 |
常見問題列表
生物活性
Spantide I 是substance P 的類似物，是選擇性的神經(jīng)激肽-1 受體 (NK1 receptor) 的拮抗劑，其對NK1 和 NK2 受體的 Ki 值分別為 230 nM 和 8150 nM。Spantide I 可減少感染角膜的1型細(xì)胞因子和增強(qiáng)2型細(xì)胞因子 IL-10，從而顯著減少角膜穿孔。靶點(diǎn)
|
NK1 230 nM (Ki) |
NK2 8150 nM (Ki) |
體內(nèi)研究
Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals.
Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNA levels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β.
| Animal Model: | Female, 8-week-old C57BL/6 (B6) and BALB/c mice. |
| Dosage: | 36 μg/mouse. |
| Administration: | IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection). |
| Result: |
At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice.
Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi. Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi. Significantly reduced the level of IL-18 mRNA at 1 day pi. |